Statement on the Planned Hepatitis B Birth Dose Vaccine Trial in Guinea-Bissau
Executive Summary
The World Health Organization (WHO) has announced plans to conduct a trial in Guinea-Bissau to evaluate the effectiveness of a hepatitis B birth dose vaccine. The trial aims to assess the impact of administering the vaccine at birth on the incidence of hepatitis B infection in infants. This report provides an overview of the planned trial, its objectives, and the potential implications for public health.
Background and Objectives
Hepatitis B is a major public health concern worldwide, with an estimated 257 million people living with chronic infection. The virus is transmitted through bodily fluids, including blood and semen, and can be acquired through vertical transmission from mother to child during birth. In Guinea-Bissau, hepatitis B is a significant cause of morbidity and mortality, particularly among children.
The planned trial aims to evaluate the effectiveness of a hepatitis B birth dose vaccine in preventing hepatitis B infection in infants. The trial will involve administering the vaccine to a cohort of newborns and comparing the incidence of hepatitis B infection in this group to a control group that does not receive the vaccine.